{"protocolSection":{"identificationModule":{"nctId":"NCT01280006","orgStudyIdInfo":{"id":"UC-MMHAP-COX-IH-2010001"},"organization":{"fullName":"University of Calgary","class":"OTHER"},"briefTitle":"Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans","officialTitle":"Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans"},"statusModule":{"statusVerifiedDate":"2011-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-01"},"primaryCompletionDateStruct":{"date":"2011-12","type":"ACTUAL"},"completionDateStruct":{"date":"2011-12","type":"ACTUAL"},"studyFirstSubmitDate":"2011-01-18","studyFirstSubmitQcDate":"2011-01-19","studyFirstPostDateStruct":{"date":"2011-01-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-12-02","lastUpdatePostDateStruct":{"date":"2011-12-05","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Marc Poulin","investigatorTitle":"Prof Dr.","investigatorAffiliation":"University of Calgary"},"leadSponsor":{"name":"University of Calgary","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The study has been designed to assess the effect of cyclooxygenase inhibition on blood pressure, cerebral blood flow, ventilation and renal hemodynamics following chronic intermittent hypoxia exposure.","detailedDescription":"The study will specifically evaluate:\n\n1. Cardiovascular effect of cyclooxygenase inhibitors on cerebral, vascular, blood pressure and homeostatic responses following chronic intermittent hypoxia exposure.\n2. Ventilatory response of cyclooxygenase inhibitors following chronic intermittent hypoxia exposure\n3. Evaluate the renal hemodynamic effect of chronic intermittent hypoxia exposure and cyclooxygenase inhibition."},"conditionsModule":{"conditions":["Obstructive Sleep Apnea","Hypertension","Cardiovascular Diseases","Stroke"],"keywords":["Obstructive Sleep Apnea","Hypoxia","Sleep","Blood Pressure","Hypertension","Myocardial Infarction","Stroke","Ventilation","Brain","Cerebral Blood Flow","Renal Blood Flow"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":12,"type":"ACTUAL"}},"armsInterventionsModule":{"interventions":[{"type":"OTHER","name":"Intermittent hypoxia","description":"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome."},{"type":"DRUG","name":"Indomethacin","description":"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.\n\nIndomethacin: 50 mg, Oral, three times per day for five days.","otherNames":["Apo-Indomethacin"]},{"type":"DRUG","name":"Celecoxib","description":"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.\n\nCelecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.","otherNames":["Celebrex"]},{"type":"DRUG","name":"Placebo","description":"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.\n\nPlacebo: Oral, three times per day for five days."}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Arterial Blood Pressure","description":"Blood pressure will be monitored during all three protocols.","timeFrame":"Six weeks"},{"measure":"Cerebral Blood Flow","description":"The cerebral blood flow will be mesauresed during each testing days of all three protocols.","timeFrame":"Six weeks"}],"secondaryOutcomes":[{"measure":"Ventilatory Response","description":"The ventilatory response will be measured during each testing days of all three protocols.","timeFrame":"Six weeks."},{"measure":"Renal Hemodynamics","description":"The renal hemodynamics will be measured during each testing days of all three protocols.","timeFrame":"Six weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male subjects\n* 18 - 45 years of age\n* Informed written consent\n\nExclusion Criteria:\n\n* Any history of cardio-respiratory diseases, ongoing medication, smoking, trauma, acute illnesses, collagen vascular diseases, rheumatoid arthritis, osteoarthritis","healthyVolunteers":true,"sex":"MALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Marc J Poulin, PhD","affiliation":"University of Calgary","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"The Laboratory of Human Cerebrovascular Physiology, HMRB 209 & HMRB 230, University of Calgary","city":"Calgary","state":"Alberta","zip":"T2N 4N1","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}}]},"referencesModule":{"references":[{"pmid":"24815497","type":"DERIVED","citation":"Beaudin AE, Pun M, Yang C, Nicholl DD, Steinback CD, Slater DM, Wynne-Edwards KE, Hanly PJ, Ahmed SB, Poulin MJ. Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea. J Am Heart Assoc. 2014 May 9;3(3):e000875. doi: 10.1161/JAHA.114.000875."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000012891","term":"Sleep Apnea Syndromes"},{"id":"D000020181","term":"Sleep Apnea, Obstructive"},{"id":"D000006973","term":"Hypertension"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000000860","term":"Hypoxia"}],"ancestors":[{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000001049","term":"Apnea"},{"id":"D000012120","term":"Respiration Disorders"},{"id":"D000012140","term":"Respiratory Tract Diseases"},{"id":"D000020919","term":"Sleep Disorders, Intrinsic"},{"id":"D000020920","term":"Dyssomnias"},{"id":"D000012893","term":"Sleep Wake Disorders"},{"id":"D000012818","term":"Signs and Symptoms, Respiratory"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9714","name":"Hypertension","asFound":"Hypertension","relevance":"HIGH"},{"id":"M4051","name":"Apnea","relevance":"LOW"},{"id":"M15384","name":"Sleep Apnea Syndromes","asFound":"Sleep Apnea","relevance":"HIGH"},{"id":"M21700","name":"Sleep Apnea, Obstructive","asFound":"Obstructive Sleep Apnea","relevance":"HIGH"},{"id":"M3875","name":"Hypoxia","asFound":"Hypoxia","relevance":"HIGH"},{"id":"M11845","name":"Myocardial Infarction","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M16045","name":"Syndrome","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M14647","name":"Respiration Disorders","relevance":"LOW"},{"id":"M14667","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M21932","name":"Parasomnias","relevance":"LOW"},{"id":"M22344","name":"Sleep Disorders, Intrinsic","relevance":"LOW"},{"id":"M22345","name":"Dyssomnias","relevance":"LOW"},{"id":"M15386","name":"Sleep Wake Disorders","relevance":"LOW"},{"id":"M15313","name":"Signs and Symptoms, Respiratory","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068579","term":"Celecoxib"},{"id":"D000007213","term":"Indomethacin"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000052246","term":"Cyclooxygenase 2 Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000006074","term":"Gout Suppressants"},{"id":"D000015149","term":"Tocolytic Agents"},{"id":"D000012102","term":"Reproductive Control Agents"}],"browseLeaves":[{"id":"M9947","name":"Indomethacin","asFound":"Correct","relevance":"HIGH"},{"id":"M277","name":"Celecoxib","asFound":"Anesthetic","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M26699","name":"Cyclooxygenase 2 Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M17559","name":"Tocolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}